PARIS--(BUSINESS WIRE)--
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2018:
| 15 February 2018: | Full year 2017 sales & results | ||||
| 26 April 2018: | First quarter 2018 sales | ||||
| 30 May 2018: | General shareholders’ meeting | ||||
| 6 June 2018: | Payment of 2017 dividend** | ||||
| 26 July 2018: | First half 2018 sales & results | ||||
| 25 October 2018: | First nine months 2018 sales |
* This financial calendar is for indicative purposes only and the Group
could change its publication dates should it deem it necessary
**
Pending approval of the Board of Directors of 14 February 2018 and of
the General shareholders’ meeting of 30 May 2018
About Ipsen
Ipsen is a global specialty-driven
biopharmaceutical group focused on innovation and specialty care. The
group develops and commercializes innovative medicines in three key
therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its
commitment to oncology is exemplified through its growing portfolio of
key therapies for prostate cancer, neuroendocrine tumors, renal cell
carcinoma and pancreatic cancer. Ipsen also has a well-established
Consumer Healthcare business. With total sales close to €1.6 billion in
2016, Ipsen sells more than 20 drugs in over 115 countries, with a
direct commercial presence in more than 30 countries. Ipsen's R&D is
focused on its innovative and differentiated technological platforms,
and centers located in the heart of leading biotechnological and life
sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The
Group has about 5,100 employees worldwide. Ipsen is listed in Paris
(Euronext: IPN) and in the United States through a Sponsored Level I
American Depositary Receipt program (ADR: IPSEY). For more information
on Ipsen, visit www.ipsen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171206005522/en/
